Physician profile
Ryan L Cox
NPI 1275983298
$4,594.39
in general payments reported to CMS, 2019-2025
20 companies · $176 in 2025
The $176 reported for 2025 was less than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $39.18 · 2021: $223 · 2022: $1,930 · 2023: $1,905 · 2024: $321 · 2025: $176.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,295 · Education: $106.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,295.23 |
| Education | $106.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $794.10 | 2020-2025 | Spravato, Invega Trinza, Invega Sustenna |
| Teva Pharmaceuticals USA, INC. | $738.55 | 2021-2025 | Austedo Xr, Uzedy, Austedo |
| Alkermes, INC. | $472.01 | 2021-2024 | Aristada, Lybalvi, Vivitrol |
| Otsuka America Pharmaceutical, INC. | $455.58 | 2021-2024 | Abilify Maintena, Rexulti |
| Neurocrine Biosciences, INC. | $377.24 | 2022-2024 | Ingrezza |
| Indivior INC. | $301.08 | 2022-2024 | Perseris, Sublocade |
| Supernus Pharmaceuticals, INC. | $256.13 | 2022-2023 | Qelbree |
| Abbvie INC. | $255.69 | 2022-2025 | Vraylar |
| Lundbeck LLC | $199.32 | 2021-2024 | Rexulti, Brintellix |
| Axsome Therapeutics, INC. | $183.71 | 2023-2024 | Auvelity |
| Takeda Pharmaceuticals U.S.A., INC. | $106.91 | 2022-2023 | Trintellix |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $100.35 | 2022-2024 | Caplyta |
| E.R. Squibb & Sons, L.L.C. | $93.77 | 2025 | Cobenfy |
| Idorsia Pharmaceuticals US INC | $76.59 | 2022-2023 | Quviviq |
| Bioxcel Therapeutics, INC. | $53.19 | 2023 | Igalmi |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $48.58 | 2023-2025 | Azstarys |
| Novo Nordisk INC | $27.70 | 2022-2023 | Wegovy |
| Owp Pharmaceuticals, INC. | $19.80 | 2023 | Lamotrigine, Subvenite |
| Mirum Pharmaceuticals, INC. | $17.28 | 2022 | |
| Lilly USA, LLC | $16.81 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Cox listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.